Literature DB >> 12454861

Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.

Florian R Greten1, Christoph K Weber, Tim F Greten, Günter Schneider, Martin Wagner, Guido Adler, Roland M Schmid.   

Abstract

BACKGROUND & AIMS: Human pancreatic adenocarcinoma has an overall poor prognosis. Therapeutic efforts are often ineffective because of late diagnosis and a high degree of chemoresistance. Overexpression of transforming growth factor alpha in the pancreas of transgenic mice causes the formation of premalignant ductal lesions and the development of invasive ductal adenocarcinoma. The aim of the present study was to explore regulation of proapoptotic and antiapoptotic signals during pancreatic tumor development in mice.
METHODS: EL-TGFalpha-hGH transgenic mice crossbred to p53-deficient mice develop ductal pancreatic adenocarcinoma resembling the human disease. During the multistep carcinogenesis up-regulation of Bcl-x(L) is evident early and persists throughout tumorigenesis as detected by Real Time PCR, Western blot analysis, and immunofluorescence.
RESULTS: Up-regulation of Bcl-x(L) is evident early in tumor development and persists throughout tumorigenesis. The transcription factors Stat3 and NF-kappaB induce increased Bcl-x(L) expression in the premalignant lesions and tumor cells. Inhibition of either transcription factor alone leads to Bcl-x(L) down-regulation in transient transfection assays. Functional analysis shows that blocking of both Stat3 and NF-kappaB together induces programmed cell death in murine pancreatic tumor cells.
CONCLUSIONS: These findings indicate that apoptosis resistance precedes formation of invasive pancreatic cancer. Therefore, combined inhibition of Stat3 and NF-kappaB might represent a novel strategy for tumor prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454861     DOI: 10.1053/gast.2002.37075

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  58 in total

1.  Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-11-09       Impact factor: 7.396

Review 2.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

3.  {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Vivek R Yadav; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

4.  Upregulation of miR-129-5p affects laryngeal cancer cell proliferation, invasiveness, and migration by affecting STAT3 expression.

Authors:  Na Shen; Xinsheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-08-29

5.  The autophagy molecule Beclin 1 maintains persistent activity of NF-κB and Stat3 in HTLV-1-transformed T lymphocytes.

Authors:  Li Chen; Dan Liu; Yang Zhang; Huan Zhang; Hua Cheng
Journal:  Biochem Biophys Res Commun       Date:  2015-08-25       Impact factor: 3.575

6.  Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.

Authors:  Yong-Wei Wang; Shuang-Jia Wang; Yi-Nan Zhou; Shang-Ha Pan; Bei Sun
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-24       Impact factor: 4.553

7.  Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation.

Authors:  Takeshi Miyatsuka; Hideaki Kaneto; Toshihiko Shiraiwa; Taka-aki Matsuoka; Kaoru Yamamoto; Ken Kato; Yumiko Nakamura; Shizuo Akira; Kiyoshi Takeda; Yoshitaka Kajimoto; Yoshimitsu Yamasaki; Eric P Sandgren; Yoshiya Kawaguchi; Christopher V E Wright; Yoshio Fujitani
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 8.  [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

Authors:  G Schneider; R M Schmid
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

9.  Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Bassel F El-Rayes; Philip A Philip; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

10.  Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Gautam Sethi; Parmeswaran Diagaradjane; Preetha Anand; Manoj K Pandey; Juri Gelovani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.